Squarepoint’s Greenwich LifeSciences GLSI Stock Holding History

Squarepoint’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,970	Closed	-$97K	–	4180
2023 Q3	$97K	Buy	+10,970	New	+$103K	﹤0.01%	3564

Other funds holding GLSI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's GLSI Position: Q4 2023 in Review

Squarepoint sold out of Greenwich LifeSciences (GLSI) in Q4 2023, closing a stake of 10,970 shares — an estimated $97K sold.

Squarepoint first reported a position in GLSI in Q3 2023 and held it in 1 quarter. The position peaked at $97K in Q3 2023. 27 funds tracked by Wall St. Rank hold GLSI as of Q4 2023.

Squarepoint reported no remaining Greenwich LifeSciences position as of Q4 2023 after selling out during the quarter.
Squarepoint sold 10,970 Greenwich LifeSciences shares in Q4 2023, an estimated $97K.
Squarepoint first reported a position in Greenwich LifeSciences in Q3 2023 and held it in 1 quarter.
Squarepoint's Greenwich LifeSciences position peaked at $97K in Q3 2023.
27 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q4 2023.

Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.